AUG 15, 2019 6:26 AM PDT

Drug Targets Early Instigators of Alzheimer Disease

WRITTEN BY: Nouran Amin

The two solidifying instigators of Alzheimer -disease (AD)—amyloid beta and the tau protein—have long been the topic of study for AD researchers. Amyloid beta contributes to AD by solidifying into toxic plaques that accumulate in the extracellular spaces of nerve tissue and the tau protein will tangle in the bodies of neurons affecting their function. These plaques and tangles are the hallmarks of AD and as a result studies are always looking for initiating drug development that targets these hallmarks.

Learn more on Alzheimer Disease:

Previous studies involving therapeutic development for AD specifically for targeting the hallmarks has often faced failure and the challenge to reverse cognitive decline as result of the disease remains at the forefront of research. Now, at the Arizona Center for Drug Discovery based at the UA College of Pharmacy, researchers have examined a molecule drug called ‘DYR219’ as a possible therapeutic for AD. DYR219 is believed to be unique in its ability to not target the hallmarks of AD but instead acts on the pathways that leads to these hallmarks. In other words, the drug acts as a prevention instead of a treatment.

“If you can block that process early, you can delay the downstream aggregation and formation of the pathologies,” says Travis Dunckley, a researcher at the ASU-Banner Neurodegenerative Disease Research Center.

Findings of the study were published in the journal Molecular Neurobiology and describes how the inhibitive effects of DYR219, or a similar drug, can eventually place a stop to AD development. By preventing or delaying the development of AD pathologies, DYR219 or a similar drug may halt the progression of Alzheimer’s in its tracks, before it damages the brain beyond repair.

“We showed a robust and significant delay in the onset of amyloid and tau pathology,” Dunckley says. “The reason I’m excited about this, especially in the face of a lot of the recent high profile clinical trial failures, is that this is really a different approach to treating the disease.”

Essentially, the drug works as a preventive measure by inhibiting a particular neuroactive enzyme called DYRK1 that holds crucial role in plaque and tangle formation in AD.

DYR219 is a powerful new drug developed to inhibit a kinase known as DYRK1. The inhibition targets leading pathologies of with Alzheimer's disease—plaques, (caused by the protein amyloid beta) and tangles, (caused by the tau protein). The drug can open new doors to preventing cognitive decline. Credit: Arizona State University, Graphic by Shireen Dooling

Source: Biodesign @ Arizona State University

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
FEB 10, 2021
Drug Discovery & Development
Ketamine Reduces Suicidal Thoughts in Patients with Depression
FEB 10, 2021
Ketamine Reduces Suicidal Thoughts in Patients with Depression
Ketamine has been known for some time for its ability to tackle depression. Now, however, researchers have found that or ...
MAR 06, 2021
Genetics & Genomics
Green Tea Extract Can Affect Facial Development in Kids With Down Syndrome
MAR 06, 2021
Green Tea Extract Can Affect Facial Development in Kids With Down Syndrome
Individuals with Down syndrome often have certain facial features. New research has suggested that green tea supplements ...
MAR 03, 2021
Drug Discovery & Development
Keeping HIV Latent
MAR 03, 2021
Keeping HIV Latent
When (HIV) human immunodeficiency virus infects cells, it can go to sleep as opposed to make viral copies of itself&mdas ...
MAR 24, 2021
Drug Discovery & Development
Three Compounds May Be Suitable for SARS-CoV-2
MAR 24, 2021
Three Compounds May Be Suitable for SARS-CoV-2
Researchers have found that that three common antiviral and antimalarial therapeutics may be effective in vitro at targe ...
MAR 30, 2021
Microbiology
A Marburg Virus Treatment Approach is Identified
MAR 30, 2021
A Marburg Virus Treatment Approach is Identified
Marburg virus causes severe hemorrhagic fever; its fatality ratio can be as high as 88 percent. Researchers may have now ...
APR 05, 2021
Drug Discovery & Development
Scientists Regenerate Missing Teeth in Mice
APR 05, 2021
Scientists Regenerate Missing Teeth in Mice
While most people have 32 teeth, around 1% of the population has more or fewer due to congenital reasons. Now, researche ...
Loading Comments...